BTK and B-cell chronic lymphocytic leukemia: Barnes and colleagues reported that ibrutinib a novel oral Bruton’s tyrosine kinase (BTK) inhibitor that has shown significant efficacy in the management of CLL was not cost-effective as initial therapy (7).